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background: Atrial fibrillation (AF) increases the risk of stroke by 5-fold, however the AF population is very heterogeneous regarding risk of stroke. 
At present, guidelines recommended risk scores are based solely on clinical variables. Cardiac biomarkers have recently been shown to carry an 
independent and strong association with increased risk of stroke in patients with AF. Our objective was to develop and validate a new AF risk score 
including clinical variables and biomarkers such as hs-troponin I and NT-proBNP to improve estimation of stroke risk.
methods: A new AF risk score taking into account both clinical variables and biomarkers was developed and validated in 14,701 AF patients 
from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Contribution of each variable in 
predicting time to stroke or systemic embolism was assessed in a Cox-regression model with point scores assigned to each variable proportional to 
model coefficients.
results: Based on 28,010 person years of follow-up and 394 stroke or systemic embolism events a new AF risk score was constructed. The most 
important predictors were (points assigned) previous stroke/TIA (3 points), NT-proBNP (400-1000 ng/L: 1 point, >1000: 2 points), hs-troponin I 
(5.4-10.1 ng/L: 1 point, >10.1: 2 points) and age ≥65 years (1 point). The new score was named BEST (BNP, Elderly, prior Stroke/TIA, Troponin). 
The BEST score yielded higher c-index than the widely used CHA2DS2VASc score (0.67 vs. 0.62) in the validation analyses. The BEST score achieved 
higher c-index as compared with the CHA2DS2VASc in subgroups with no prior stroke (0.65 vs. 0.59) and in patients with a low time in therapeutic 
range (<55%; 0.68 vs. 0.63). The net reclassification improvement was positive and yielded a significant improvement of 24% (95% CI [15%, 33%]).
conclusions: A novel risk score for predicting stroke or systemic embolism using clinical and biomarker data, named BEST, was developed in a 
large cohort of patients with AF. The BEST risk score performed better than presently used clinically based risk scores and may improve treatment 
decisions in patients with AF.
